ACADIA Pharmaceuticals, Inc. (ACAD)
28.02
+0.16
(+0.57%)
USD |
NASDAQ |
Sep 04, 16:00
28.01
-0.01
(-0.04%)
After-Hours: 20:00
ACADIA Pharmaceuticals Research and Development Expense (Quarterly) : 81.56M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 81.56M |
| March 31, 2026 | 76.87M |
| December 31, 2025 | 84.76M |
| September 30, 2025 | 87.83M |
| June 30, 2025 | 77.95M |
| March 31, 2025 | 78.26M |
| December 31, 2024 | 100.73M |
| September 30, 2024 | 66.61M |
| June 30, 2024 | 76.23M |
| March 31, 2024 | 59.68M |
| December 31, 2023 | 66.74M |
| September 30, 2023 | 156.96M |
| June 30, 2023 | 58.77M |
| March 31, 2023 | 69.14M |
| December 31, 2022 | 75.74M |
| September 30, 2022 | 81.34M |
| June 30, 2022 | 75.65M |
| March 31, 2022 | 128.86M |
| December 31, 2021 | 67.08M |
| September 30, 2021 | 58.56M |
| June 30, 2021 | 56.94M |
| March 31, 2021 | 56.97M |
| December 31, 2020 | 9.316M |
| September 30, 2020 | 67.28M |
| June 30, 2020 | 64.30M |
| Date | Value |
|---|---|
| March 31, 2020 | 72.64M |
| December 31, 2019 | 57.52M |
| September 30, 2019 | 62.62M |
| June 30, 2019 | 67.32M |
| March 31, 2019 | 52.92M |
| December 31, 2018 | 48.18M |
| September 30, 2018 | 53.11M |
| June 30, 2018 | 46.59M |
| March 31, 2018 | 39.28M |
| December 31, 2017 | 43.18M |
| September 30, 2017 | 36.42M |
| June 30, 2017 | 34.18M |
| March 31, 2017 | 35.41M |
| December 31, 2016 | 30.22M |
| September 30, 2016 | 25.81M |
| June 30, 2016 | 20.48M |
| March 31, 2016 | 22.78M |
| December 31, 2015 | 20.47M |
| September 30, 2015 | 18.73M |
| June 30, 2015 | 18.38M |
| March 31, 2015 | 16.30M |
| December 31, 2014 | 18.18M |
| September 30, 2014 | 16.95M |
| June 30, 2014 | 13.80M |
| March 31, 2014 | 11.67M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Incyte Corp. | 497.47M |
| Agios Pharmaceuticals, Inc. | 99.40M |
| Biogen, Inc. | 461.70M |
| Insmed, Inc. | 210.03M |
| Arcutis Biotherapeutics, Inc. | 20.36M |